DBI-2013

N/A

Report date: 2022/08/24 20:00:31

Base Information

Drug NameDBI-2013
Drug Alias NameDI-2013
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionT-cell-specific surface glycoprotein CD28 inhibitors
TargetsT-cell-specific surface glycoprotein CD28
Therapy Area/IndicationsDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesDiabetogen BiosciencesAbgenix Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDiabetogen Biosciences
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 1

Other Information

ATC CodeN/A
Related LinksN/A